Fourth-quarter revenue up 25% and operating profit up 142%...record high
Biopharmaceutical sales grow 24%
Revenue target of 5.3 trillion won set for this year

For the first time in its history, Celltrion has simultaneously exceeded 4 trillion won in annual revenue and 1 trillion won in operating profit.


In a disclosure on the 5th, Celltrion announced that on a consolidated basis it posted 2025 revenue of 4.1625 trillion won and operating profit of 1.1685 trillion won. Revenue increased 17% year-on-year, while operating profit surged 137.5%. The annual operating margin came in at 28.1%, up 14.3 percentage points from a year earlier.

Celltrion corporate logo image. Celltrion

Celltrion corporate logo image. Celltrion

View original image

Its performance in the fourth quarter of last year also renewed the company’s all-time quarterly highs. Fourth-quarter revenue was 1.3302 trillion won, up 25.1% from the same period a year earlier, and operating profit was 475.2 billion won, a 142% increase. Both figures exceeded the company’s earlier guidance of 1.2839 trillion won in revenue and 472.2 billion won in operating profit.


This improvement in results was driven by the stable growth of existing flagship products, combined with a rapid increase in the share of new high-margin products. While Remsima, Truxima, and Herzuma maintained solid sales momentum, new products such as Remsima SC, Yuflyma, Vegzelma, Zympentra, Steqima, Omlyclo, and Stoboclo/Osenbelt successfully established themselves in the market. As a result, global sales of biopharmaceuticals last year rose 24% year-on-year to 3.8638 trillion won, with new products accounting for 54% of total sales.


By product, Remsima achieved market shares of 59% in Europe and 30% in the United States. Truxima secured market shares in the 30% range in both the United States and Europe, growing 17.1% year-on-year. Herzuma, while maintaining the No. 1 market share in Europe, also achieved a 75% share in Japan, posting a 10.1% increase from the previous year. Yuflyma maintained its No. 1 market share in Europe and grew 44%, supported by expanded prescriptions in the United States, while Vegzelma also kept its No. 1 market share in Europe and grew 66.8% on the back of diversified sales channels in the United States.


Five new products that were launched in the second half of last year or were in the launch-preparation stage in certain regions surpassed 300 billion won in annual sales. Listing as preferred drugs with major U.S. pharmacy benefit managers and successful tender bids in individual European countries contributed to the sales expansion. The company expects growth to accelerate further this year as prescriptions for these products continue throughout the year.


Profitability also improved markedly. In the fourth quarter of last year, the cost-of-goods-sold ratio fell to 35.8%, about 3 percentage points lower than in the third quarter. According to the company, the cost ratio, which had approached 63% in the fourth quarter of 2023 immediately after the merger, improved significantly due to the depletion of high-cost inventory and the completion of R&D cost amortization, effectively eliminating the impact of the merger.


Celltrion has set this year’s revenue target at 5.3 trillion won. The company plans to stably supply 11 biosimilar products currently being provided to the global market through its own direct sales network and production facilities, while strengthening its market dominance through country-specific strategies. It will reduce the share of high-cost products and, through a bidding strategy focused on new high-margin products, aims to increase the share of new products in total sales to around 70% this year.


At its Branchburg, New Jersey manufacturing facility in the United States, contract manufacturing revenue is expected to begin in earnest this year. The company plans to supply biopharmaceuticals worth about 678.7 billion won by 2029 and to use the site as a base for expanding both its own product business and its contract development and manufacturing operations.



A Celltrion official said, “We achieved record results thanks to merger synergies and the successful market penetration of new products,” adding, “This year as well, we will maintain our high-growth trajectory based on structural cost improvements and the impact of new product launches.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing